Three months after regaining global rights to EZH2 inhibitor tazemetostat, Epizyme Inc. presented updated phase I data demonstrating a deepening response rate over time in patients with advanced B-cell non-Hodgkin lymphoma (NHL) and reiterated plans to advance into phase II testing in NHL and in solid tumors that are INI1-deficient.